Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study
Authors
Keywords
-
Journal
MEDICINE
Volume 100, Issue 29, Pages e26769
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-08-06
DOI
10.1097/md.0000000000026769
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial
- (2021) Rodrigo P. Mello et al. JOURNAL OF PSYCHIATRIC RESEARCH
- The identification, assessment and management of difficult-to-treat depression: An international consensus statement
- (2020) R.H. McAllister-Williams et al. JOURNAL OF AFFECTIVE DISORDERS
- Editorial for Treatment-Resistant Depression (TRD)
- (2019) Siegfried Kasper et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial
- (2019) Jennifer L. Phillips et al. AMERICAN JOURNAL OF PSYCHIATRY
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
- (2019) Vanina Popova et al. AMERICAN JOURNAL OF PSYCHIATRY
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
- (2019) Maggie Fedgchin et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
- (2019) Ella J. Daly et al. JAMA Psychiatry
- Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
- (2018) Mark J. Niciu et al. JOURNAL OF AFFECTIVE DISORDERS
- Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression
- (2018) Wei Zheng et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression
- (2018) Sonia Vidal et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Pharmacological Approaches for Treatment-resistant Bipolar Disorder
- (2015) Shi Hui Poon et al. Current Neuropharmacology
- A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
- (2014) Kyle A.B. Lapidus et al. BIOLOGICAL PSYCHIATRY
- Do the dissociative side effects of ketamine mediate its antidepressant effects?
- (2014) David A. Luckenbaugh et al. JOURNAL OF AFFECTIVE DISORDERS
- The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS
- (2011) Gerald W. Valentine et al. PSYCHIATRY RESEARCH-NEUROIMAGING
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
- (2010) Nancy Diazgranados et al. ARCHIVES OF GENERAL PSYCHIATRY
- Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning
- (2009) Madhukar H. Trivedi et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started